|
|
|
|
| LEADER |
01890 am a22002773u 4500 |
| 001 |
102913 |
| 042 |
|
|
|a dc
|
| 100 |
1 |
0 |
|a Andreou, Ioannis
|e author
|
| 100 |
1 |
0 |
|a Institute for Medical Engineering and Science
|e contributor
|
| 100 |
1 |
0 |
|a Andreou, Ioannis
|e contributor
|
| 100 |
1 |
0 |
|a Edelman, Elazer R.
|e contributor
|
| 700 |
1 |
0 |
|a Sun, Xinghui
|e author
|
| 700 |
1 |
0 |
|a Stone, Peter H.
|e author
|
| 700 |
1 |
0 |
|a Edelman, Elazer R.
|e author
|
| 700 |
1 |
0 |
|a Feinberg, Mark W.
|e author
|
| 245 |
0 |
0 |
|a miRNAs in atherosclerotic plaque initiation, progression, and rupture
|
| 260 |
|
|
|b Cell Press/Elsevier,
|c 2016-06-03T14:24:21Z.
|
| 856 |
|
|
|z Get fulltext
|u http://hdl.handle.net/1721.1/102913
|
| 520 |
|
|
|a Atherosclerosis is a chronic immune-inflammatory disorder that integrates multiple cell types and a diverse set of inflammatory mediators. miRNAs are emerging as important post-transcriptional regulators of gene expression in most, if not all, vertebrate cells, and constitute central players in many physiological and pathological processes. Rapidly accumulating experimental studies reveal their key role in cellular and molecular processes related to the development of atherosclerosis. We review current evidence for the involvement of miRNAs in early atherosclerotic lesion formation and in plaque rupture and erosion. We conclude with a perspective on the clinical relevance, therapeutic opportunities, and future challenges of miRNA biology in understanding the pathogenesis of this complex disease.
|
| 520 |
|
|
|a National Institutes of Health (U.S.) (NIH grant HL115141)
|
| 520 |
|
|
|a National Institutes of Health (U.S.) (NIH grant HL117994)
|
| 520 |
|
|
|a National Institutes of Health (U.S.) (NIH grant GM49039)
|
| 520 |
|
|
|a Massachusetts Institute of Technology. George D. Behrakis Cardiovascular Research Program
|
| 546 |
|
|
|a en_US
|
| 655 |
7 |
|
|a Article
|
| 773 |
|
|
|t Trends in Molecular Medicine
|
